LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
LeMaitre Vascular, Inc.NASDAQ: LMAT
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables broadly unchanged from a year ago
Net receivables stood at $35.77M at the end of Q1 FY2026, up 1.9% from a year earlier and up 6.4% from the prior quarter. Over 3 fiscal years it compounded at +15.1% a year.
Context
- Net receivables amounted to 5.7% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +1.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 33.61M USD
- Year-over-year change
- +11.8%
- 4-year CAGR
- +14.4%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.61M | +11.8% |
| FY2024 | 2024-12-31 | 30.06M | +19.9% |
| FY2023 | 2023-12-31 | 25.06M | +13.7% |
| FY2022 | 2022-12-31 | 22.04M | +12.3% |
| FY2021 | 2021-12-31 | 19.63M | — |
Net Receivables vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's Mar 2026 net receivables of $35.77M is the 7th highest of the 8 companies compared; the peer median is $190.41M.
- Its year-over-year change of +1.9% is the 4th highest of 8, against a peer median of -7.0%.
- Net receivables amounts to 5.7% of total assets for LMAT, versus a peer median of 8.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.05B | +8.3% | +14.1% | 6.7% | |
| Jun 2026 | $364.61M | -29.0% | -5.4% | 5.4% | |
| Jul 2026 | $224M | -96.4% | +3.5% | 0.2% | |
| Jun 2026 | $190.41M | +8.5% | -2.2% | 9.6% | |
| Mar 2026 | $105.62M | +10.3% | +14.2% | 12.0% | |
| Feb 2026 | $45.55M | -7.0% | -8.6% | 17.5% | |
| Mar 2026 | $35.77M | +1.9% | +15.1% | 5.7% | |
| Sep 2026 | $0 | -100.0% | +7.8% | — | |
| Peer median (excluding LMAT) | $190.41M | -7.0% | +3.5% | 8.2% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13.86M | 19.13M | 24.27M | 25.61M | 28.24M |
| Short-term Investments | 56.1M | 63.56M | 80.81M | 274.11M | 330.88M |
| Net Receivables | 19.63M | 22.04M | 25.06M | 30.06M | 33.61M |
| Inventory | 40.65M | 45.28M | 52.33M | 55.94M | 70.42M |
| Other Current Assets | 5.46M | 11.72M | 12.13M | 8.99M | 5.08M |
| Total Current Assets | 139.88M | 161.73M | 194.6M | 402.19M | 468.23M |
| Property, Plant & Equipment (Net) | 32.13M | 33.54M | 39.78M | 41.57M | 42.76M |
| Goodwill | 65.95M | 65.95M | 65.95M | 65.95M | 65.95M |
| Intangible Assets | 52.71M | 46.53M | 41.71M | 35.82M | 33.09M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 1.57M | 1.75M | 1M | 1.43M | 759K |
| Other Non-current Assets | 568K | 991K | 3.74M | 4.87M | 4.91M |
| Total Non-current Assets | 152.92M | 148.74M | 152.18M | 149.63M | 147.46M |
| Total Assets | 292.8M | 310.48M | 346.78M | 551.82M | 615.69M |
| Account Payables | 2.34M | 2.9M | 3.73M | 1.76M | 3.65M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 10.79M | 11.22M | 13.74M | 15.76M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.27M | 573K | 24K | 1.43M | 322K |
| Total Current Liabilities | 21.81M | 25.33M | 29.88M | 30.61M | 36.32M |
| Long-term Debt | 0 | 0 | 0 | 167.77M | 168.65M |
| Deferred Tax Liabilities | 70K | 69K | 107K | 85K | 1.74M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.7M | 2.17M | 2.27M | 831K | 1.47M |
| Total Non-current Liabilities | 16.84M | 16.95M | 19M | 183.92M | 185.85M |
| Total Liabilities | 38.65M | 42.28M | 48.88M | 214.53M | 222.17M |
| Common Stock | 235K | 237K | 239K | 242K | 244K |
| Retained Earnings | 88.13M | 97.77M | 115.43M | 145.09M | 184.72M |
| Accumulated OCI | (3.44M) | (6.03M) | (4.63M) | (6.18M) | (2.41M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 254.15M | 268.2M | 297.9M | 337.29M | 393.52M |
| Total Debt | 15.94M | 16.6M | 19.1M | 185.69M | 185.59M |
| Net Debt | 2.08M | (2.54M) | (5.17M) | 160.08M | 157.35M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.